M. Richie

发表

Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia

Z. Estrov, M. Andreeff, H. Kantarjian, 2018, American journal of hematology.

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

M. Konopleva, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2016, American journal of hematology.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

I. Bernstein, E. Estey, M. Berger, 2005, Cancer.

Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer

H. Gómez, F. Kabbinavar, V. Goodman, 2008 .

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, The Lancet. Haematology.

A randomized phase II trial of 5-day versus 10-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia

Farhad, Z. Estrov, H. Kantarjian, 2019 .

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Cancer.

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Jorge Cortes, Guillermo Garcia-Manero, Gautam Borthakur, 2013, Blood.

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006 .

Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin to patients < 60 years old with untreated acute myeloid leukemia.

M. Berger, G. Juliusson, M. Tallman, 2002 .

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

H. Gómez, S. Johnston, V. Goodman, 2013, Breast Cancer Research and Treatment.

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia

M. Konopleva, H. Kantarjian, J. Cortes, 2018, British journal of haematology.

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2010, Leukemia & lymphoma.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

M. Konopleva, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias.

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .